Canada to review Theratechnologies' Egrifta new drug submission
This article was originally published in Scrip
Executive Summary
Health Canada has accepted for review Theratechnologies' new drug submission for Egrifta (tesamorelin), which was filed in late June. The product, a once-daily injection of an analogue of the growth hormone-releasing factor (GHRF), is indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.